We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

42 hedge funds and large institutions have $119M invested in Strongbridge Biopharma plc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more call options, than puts

Call options by funds: $51K | Put options by funds: $29K

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

14% less funds holding

Funds holding: 4942 (-7)

20% less capital invested

Capital invested by funds: $149M → $119M (-$29.9M)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
42
Holders Change
-7
Holders Change %
-14.29%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
14
Reduced
16
Closed
16
Calls
$51K
Puts
$29K
Net Calls
+$22K
Net Calls Change
-$6K
Name Holding Trade Value Shares
Change
Change in
Stake
SIM
26
Spark Investment Management
New York
$146K +$160K +32,800 New
BCM
27
BlueCrest Capital Management
Jersey
$127K -$363K -74,369 -72%
OAM
28
Oxford Asset Management
United Kingdom
$110K +$120K +24,593 New
OC
29
Oppenheimer & Co
New York
$107K -$405 -83 -0.3%
BCM
30
Bayesian Capital Management
New York
$102K +$44.9K +9,200 +68%
Goldman Sachs
31
Goldman Sachs
New York
$87K -$499K -102,249 -84%
Stifel Financial
32
Stifel Financial
Missouri
$73K +$83.6K +17,125 New
ProShare Advisors
33
ProShare Advisors
Maryland
$72K -$14.9K -3,054 -16%
Janney Montgomery Scott
34
Janney Montgomery Scott
Pennsylvania
$63K +$9.76K +2,000 +17%
RG
35
Redmile Group
California
$56K +$61K +12,500 New
Morgan Stanley
36
Morgan Stanley
New York
$50K -$133K -27,194 -71%
TRCT
37
Tower Research Capital (TRC)
New York
$25K +$27.5K +5,629 New
CG
38
Cutler Group
California
$19K +$21.5K +4,400 New
Bank of America
39
Bank of America
North Carolina
$12K -$41.2K -8,435 -76%
UBS Group
40
UBS Group
Switzerland
$11K +$9.26K +1,896 +422%
Barclays
41
Barclays
United Kingdom
$1K -$352K -72,034 -100%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$139 +$151 +31 New
LSC
43
Lyon Street Capital
California
-$13.9M -2,858,928 Closed
VC
44
Vivo Capital
California
-$4.45M -918,132 Closed
GPCM
45
Granite Point Capital Management
Massachusetts
-$2.75M -567,895 Closed
Marshall Wace
46
Marshall Wace
United Kingdom
-$1.29M -265,934 Closed
IECM
47
Intrinsic Edge Capital Management
Illinois
-$970K -200,000 Closed
Renaissance Technologies
48
Renaissance Technologies
New York
-$402K -82,800 Closed
AA
49
ALPS Advisors
Colorado
-$401K -82,657 Closed
ECM
50
Element Capital Management
New York
-$249K -51,372 Closed

SBBP Hedge Fund Activity: Q4 2018 in Review

42 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2018, worth a combined $119M — down 20% from $149M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SBBP and 9 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.

The largest buyer was 683 Capital Management, adding an estimated $2.68M. The largest seller was Lyon Street Capital, exiting entirely with an estimated $13.9M sold.

  • 42 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2018, down from 49 in Q3 2018.
  • Funds reported $119M of Strongbridge Biopharma plc. stock for Q4 2018, down 20% quarter-over-quarter.
  • 9 funds opened new Strongbridge Biopharma plc. positions in Q4 2018 and 16 closed out, a net change of -7 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q4 2018 was 683 Capital Management, an estimated $2.68M added.
  • The largest Strongbridge Biopharma plc. seller in Q4 2018 was Lyon Street Capital, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2018.